Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

BTMD vs GDRX vs HIMS vs AMWL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BTMD
biote Corp.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$92M
5Y Perf.-79.2%
GDRX
GoodRx Holdings, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$973M
5Y Perf.-92.9%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+107.3%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$129M
5Y Perf.-97.5%

BTMD vs GDRX vs HIMS vs AMWL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BTMD logoBTMD
GDRX logoGDRX
HIMS logoHIMS
AMWL logoAMWL
IndustryMedical - Care FacilitiesMedical - Healthcare Information ServicesMedical - Equipment & ServicesMedical - Healthcare Information Services
Market Cap$92M$973M$6.63B$129M
Revenue (TTM)$188M$788M$2.35B$182M
Net Income (TTM)$16M$29M$128M$-88M
Gross Margin70.1%81.0%69.7%38.7%
Operating Margin15.4%12.4%4.6%-50.6%
Forward P/E2.8x9.0x51.5x
Total Debt$110M$60M$1.12B$5M
Cash & Equiv.$24M$262M$229M$182M

BTMD vs GDRX vs HIMS vs AMWLLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BTMD
GDRX
HIMS
AMWL
StockApr 21May 26Return
biote Corp. (BTMD)10020.8-79.2%
GoodRx Holdings, In… (GDRX)1007.1-92.9%
Hims & Hers Health,… (HIMS)100207.3+107.3%
American Well Corpo… (AMWL)1002.5-97.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: BTMD vs GDRX vs HIMS vs AMWL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BTMD leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. American Well Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. HIMS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
BTMD
biote Corp.
The Value Play

BTMD carries the broadest edge in this set and is the clearest fit for value and quality.

  • Better valuation composite
  • 8.3% margin vs AMWL's -48.2%
  • 2.3% yield; the other 3 pay no meaningful dividend
  • 15.1% ROA vs AMWL's -25.1%, ROIC 11.3% vs -95.1%
Best for: value and quality
GDRX
GoodRx Holdings, Inc.
The Income Pick

GDRX is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.58
Best for: income & stability
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 161.9% 10Y total return vs BTMD's -79.2%
  • 59.0% revenue growth vs BTMD's -2.5%
Best for: growth exposure and long-term compounding
AMWL
American Well Corporation
The Defensive Pick

AMWL is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
  • Beta 1.47, current ratio 3.37x
  • Beta 1.47 vs HIMS's 2.40, lower leverage
  • +14.3% vs HIMS's -51.0%
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs BTMD's -2.5%
ValueBTMD logoBTMDBetter valuation composite
Quality / MarginsBTMD logoBTMD8.3% margin vs AMWL's -48.2%
Stability / SafetyAMWL logoAMWLBeta 1.47 vs HIMS's 2.40, lower leverage
DividendsBTMD logoBTMD2.3% yield; the other 3 pay no meaningful dividend
Momentum (1Y)AMWL logoAMWL+14.3% vs HIMS's -51.0%
Efficiency (ROA)BTMD logoBTMD15.1% ROA vs AMWL's -25.1%, ROIC 11.3% vs -95.1%

BTMD vs GDRX vs HIMS vs AMWL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BTMDbiote Corp.
FY 2025
Product Revenue
78.2%$187M
Dietary Supplements
17.9%$43M
Service Revenue
2.2%$5M
Other Service Revenue
1.2%$3M
Training Service Revenue
0.5%$1M
GDRXGoodRx Holdings, Inc.
FY 2024
Prescription Transactions Revenue
84.3%$578M
Subscription Revenue
12.6%$87M
Other Revenue
3.1%$21M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M

BTMD vs GDRX vs HIMS vs AMWL — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBTMDLAGGINGAMWL

Income & Cash Flow (Last 12 Months)

Evenly matched — BTMD and GDRX each lead in 2 of 6 comparable metrics.

HIMS is the larger business by revenue, generating $2.3B annually — 12.9x AMWL's $182M. BTMD is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
RevenueTrailing 12 months$188M$788M$2.3B$182M
EBITDAEarnings before interest/tax$32M$184M$164M-$59M
Net IncomeAfter-tax profit$16M$29M$128M-$88M
Free Cash FlowCash after capex$29M$132M$73M-$42M
Gross MarginGross profit ÷ Revenue+70.1%+81.0%+69.7%+38.7%
Operating MarginEBIT ÷ Revenue+15.4%+12.4%+4.6%-50.6%
Net MarginNet income ÷ Revenue+8.3%+3.7%+5.5%-48.2%
FCF MarginFCF ÷ Revenue+15.2%+16.7%+3.1%-22.9%
Rev. Growth (YoY)Latest quarter vs prior year-8.3%-4.4%+28.4%-100.0%
EPS Growth (YoY)Latest quarter vs prior year-83.8%-1.3%-27.3%+44.5%
Evenly matched — BTMD and GDRX each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — BTMD and GDRX and AMWL each lead in 2 of 6 comparable metrics.

At 2.8x trailing earnings, BTMD trades at a 94% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than HIMS's 42.7x.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
Market CapShares × price$92M$973M$6.6B$129M
Enterprise ValueMkt cap + debt − cash$178M$771M$7.5B-$48M
Trailing P/EPrice ÷ TTM EPS2.82x33.29x50.32x-1.30x
Forward P/EPrice ÷ next-FY EPS est.8.98x51.51x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple4.54x4.01x42.68x
Price / SalesMarket cap ÷ Revenue0.48x1.22x2.82x0.52x
Price / BookPrice ÷ Book value/share1.65x12.25x0.50x
Price / FCFMarket cap ÷ FCF3.05x5.92x89.61x
Evenly matched — BTMD and GDRX and AMWL each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

BTMD leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), BTMD scores 6/9 vs HIMS's 4/9, reflecting solid financial health.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
ROE (TTM)Return on equity+4.8%+23.7%-33.5%
ROA (TTM)Return on assets+15.1%+1.9%+6.0%-25.1%
ROICReturn on invested capital+11.3%+13.0%+10.7%-95.1%
ROCEReturn on capital employed+53.3%+8.8%+10.9%-36.6%
Piotroski ScoreFundamental quality 0–96646
Debt / EquityFinancial leverage0.10x2.07x0.02x
Net DebtTotal debt minus cash$86M-$202M$892M-$178M
Cash & Equiv.Liquid assets$24M$262M$229M$182M
Total DebtShort + long-term debt$110M$60M$1.1B$5M
Interest CoverageEBIT ÷ Interest expense3.02x3.61x-239.18x
BTMD leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs AMWL's -42.2% — a key indicator of consistent wealth creation.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
YTD ReturnYear-to-date-15.4%+3.3%-23.2%+59.8%
1-Year ReturnPast 12 months-37.4%-25.1%-51.0%+14.3%
3-Year ReturnCumulative with dividends-69.7%-38.4%+116.6%-80.7%
5-Year ReturnCumulative with dividends-79.1%-91.8%+137.6%-97.2%
10-Year ReturnCumulative with dividends-79.2%-94.4%+161.9%-98.3%
CAGR (3Y)Annualised 3-year return-32.8%-14.9%+29.4%-42.2%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

AMWL leads this category, winning 2 of 2 comparable metrics.

AMWL is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
Beta (5Y)Sensitivity to S&P 5001.73x1.58x2.40x1.47x
52-Week HighHighest price in past year$4.75$5.81$70.43$9.15
52-Week LowLowest price in past year$1.27$1.77$13.74$3.71
% of 52W HighCurrent price vs 52-week peak+44.0%+48.9%+36.4%+84.7%
RSI (14)Momentum oscillator 0–10062.266.154.567.1
Avg Volume (50D)Average daily shares traded265K2.3M34.9M59K
AMWL leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

GDRX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: GDRX as "Hold", HIMS as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 12.3% for GDRX (target: $3). BTMD is the only dividend payer here at 2.25% yield — a key consideration for income-focused portfolios.

MetricBTMD logoBTMDbiote Corp.GDRX logoGDRXGoodRx Holdings, …HIMS logoHIMSHims & Hers Healt…AMWL logoAMWLAmerican Well Cor…
Analyst RatingConsensus buy/hold/sellHoldHold
Price TargetConsensus 12-month target$3.19$29.67
# AnalystsCovering analysts2419
Dividend YieldAnnual dividend ÷ price+2.3%
Dividend StreakConsecutive years of raises01
Dividend / ShareAnnual DPS$0.05
Buyback YieldShare repurchases ÷ mkt cap+3.7%+21.3%+1.4%+0.0%
GDRX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

BTMD leads in 1 of 6 categories (Profitability & Efficiency). HIMS leads in 1 (Total Returns). 2 tied.

Best Overallbiote Corp. (BTMD)Leads 1 of 6 categories
Loading custom metrics...

BTMD vs GDRX vs HIMS vs AMWL: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BTMD or GDRX or HIMS or AMWL a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 5% for biote Corp. (BTMD). biote Corp. (BTMD) offers the better valuation at 2. 8x trailing P/E, making it the more compelling value choice. Analysts rate GoodRx Holdings, Inc. (GDRX) a "Hold" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BTMD or GDRX or HIMS or AMWL?

On trailing P/E, biote Corp.

(BTMD) is the cheapest at 2. 8x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BTMD or GDRX or HIMS or AMWL?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BTMD or GDRX or HIMS or AMWL?

By beta (market sensitivity over 5 years), American Well Corporation (AMWL) is the lower-risk stock at 1.

47β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 64% more volatile than AMWL relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BTMD or GDRX or HIMS or AMWL?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -2. 5% for biote Corp. (BTMD). On earnings-per-share growth, the picture is similar: biote Corp. grew EPS 703. 5% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BTMD or GDRX or HIMS or AMWL?

biote Corp.

(BTMD) is the more profitable company, earning 14. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 14. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTMD leads at 18. 5% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BTMD or GDRX or HIMS or AMWL more undervalued right now?

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 42. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

08

Which pays a better dividend — BTMD or GDRX or HIMS or AMWL?

In this comparison, BTMD (2.

3% yield) pays a dividend. GDRX, HIMS, AMWL do not pay a meaningful dividend and should not be held primarily for income.

09

Is BTMD or GDRX or HIMS or AMWL better for a retirement portfolio?

For long-horizon retirement investors, biote Corp.

(BTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 3% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BTMD: -79. 2%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BTMD and GDRX and HIMS and AMWL?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BTMD is a small-cap deep-value stock; GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; AMWL is a small-cap quality compounder stock. BTMD pays a dividend while GDRX, HIMS, AMWL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BTMD

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

GDRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 48%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BTMD and GDRX and HIMS and AMWL on the metrics below

Revenue Growth>
%
(BTMD: -8.3% · GDRX: -4.4%)
Net Margin>
%
(BTMD: 8.3% · GDRX: 3.7%)
P/E Ratio<
x
(BTMD: 2.8x · GDRX: 33.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.